Showing results (2321-2330 of 5,702) with videos related to

Sort By:
Pageof 571
The Oncologist|August 19, 2018
Permanent Chemotherapy-Induced Alopecia in Patients with Breast Cancer: A 3-Year Prospective Cohort StudyDanbee Kang, Im-Ryung Kim, Eun-Kyung Choi, et al.
The Oncologist|May 30, 2019
Docetaxel, Oxaliplatin, and 5-Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long-Term Follow-UpAri Joseph Rosenberg, Alfred Rademaker, Howard S Hochster, et al.
The Oncologist|May 30, 2019
An Eastern Hepatobiliary Surgery Hospital Microvascular Invasion Scoring System in Predicting Prognosis of Patients with Hepatocellular Carcinoma and Microvascular Invasion After R0 Liver Resection: A Large-Scale, Multicenter StudyXiu-Ping Zhang, Kang Wang, Xu-Biao Wei, et al.
The Oncologist|June 1, 2019
Prognostic Nomogram and Patterns of Use of FOLFIRI-Aflibercept in Advanced Colorectal Cancer: A Real-World Data AnalysisAna Fernández Montes, Carlos López López, Guillem Argilés Martínez, et al.
The Oncologist|March 18, 2022
Phase II Study of Continued Trastuzumab Plus Irinotecan in Patients with HER2-positive Gastric Cancer Previously Treated with Trastuzumab (HGCSG 1201)Yasuyuki Kawamoto, Satoshi Yuki, Takashi Meguro, et al.
The Oncologist|March 19, 2022
Reinduction of an Anti-EGFR-based First-line Regimen in Patients with RAS Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino StudyGiovanni Fucà, Alessandra Raimondi, Michele Prisciandaro, et al.
The Oncologist|March 19, 2022
Risk Factors for Hospitalizations Among Older Adults with Gastrointestinal CancersDaneng Li, Can-Lan Sun, Rebecca Allen, et al.
The Oncologist|March 19, 2022
Physician Perceptions of the FDA's Breakthrough Therapy Designation: An UpdateRyan S Paquin, Vanessa Boudewyns, Amie C O'Donoghue, et al.
The Oncologist|April 5, 2022
The Essentials of MultiomicsJohn L Marshall, Beth N Peshkin, Takayuki Yoshino, et al.
The Oncologist|April 5, 2022
Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical TrialMarla Lipsyc-Sharf, Fang-Shu Ou, Matthew B Yurgelun, et al.
Pageof 571